164 related articles for article (PubMed ID: 22999608)
1. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Parekh JG; Newsom TH; Nielsen S
J Cataract Refract Surg; 2012 Oct; 38(10):1864-7. PubMed ID: 22999608
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
4. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Bertino JS; Zhang JZ
Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
[TBL] [Abstract][Full Text] [Related]
5. Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Majmudar PA; Clinch TE
Cornea; 2014 May; 33(5):457-62. PubMed ID: 24637269
[TBL] [Abstract][Full Text] [Related]
6. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
Moshirfar M; Feiz V; Vitale AT; Wegelin JA; Basavanthappa S; Wolsey DH
Ophthalmology; 2007 Apr; 114(4):686-91. PubMed ID: 17184840
[TBL] [Abstract][Full Text] [Related]
7. Endophthalmitis.
Bohigian GM
Ophthalmology; 2008 Feb; 115(2):413-4; author reply 414. PubMed ID: 18243911
[No Abstract] [Full Text] [Related]
8. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
Espiritu CR; Caparas VL; Bolinao JG
J Cataract Refract Surg; 2007 Jan; 33(1):63-8. PubMed ID: 17189795
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
Lane SS; Osher RH; Masket S; Belani S
J Cataract Refract Surg; 2008 Sep; 34(9):1451-9. PubMed ID: 18721703
[TBL] [Abstract][Full Text] [Related]
10. The role of besifloxacin in the treatment of bacterial conjunctivitis.
Mahvan TD; Hornecker JR; Buckley WA; Clark S
Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460
[TBL] [Abstract][Full Text] [Related]
11. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
Arbisser LB
J Cataract Refract Surg; 2008 Jul; 34(7):1114-20. PubMed ID: 18571078
[TBL] [Abstract][Full Text] [Related]
12. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.
Schechter BA; Parekh JG; Trattler W
J Ocul Pharmacol Ther; 2015 Mar; 31(2):114-21. PubMed ID: 25409447
[TBL] [Abstract][Full Text] [Related]
13. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Jensen MK; Fiscella RG; Moshirfar M; Mooney B
J Cataract Refract Surg; 2008 Sep; 34(9):1460-7. PubMed ID: 18721704
[TBL] [Abstract][Full Text] [Related]
14. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
15. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
16. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
17. Dropless Cataract Surgery: What Are the Potential Downsides?
Stringham JD; Flynn HW; Schimel AM; Banta JT
Am J Ophthalmol; 2016 Apr; 164():viii-x. PubMed ID: 26895602
[No Abstract] [Full Text] [Related]
18. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
O'Brien TP
Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
[TBL] [Abstract][Full Text] [Related]
19. Reply: To PMID 24054967.
Matsuura K; Miyoshi T; Suto C; Akura J; Inoue Y
J Cataract Refract Surg; 2014 Mar; 40(3):509. PubMed ID: 24581786
[No Abstract] [Full Text] [Related]
20. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Yoshida J; Kim A; Pratzer KA; Stark WJ
J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]